Program
Clarithromycin
Also written as “clarithromycin”, “Clarithromycin ER 500 mg tablets” and “Clarithromycin 500mg”.
Its studies are mostly in Mycobacterium avium-intracellulare Infection · Infections · HIV Infections · Bronchiectasis · Crohn Disease, led by 19 companies.
Drug pageClarithromycin: every studyMany companies study it; this page follows only the 39 they lead. All 152 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 50 open or running | phase 3since Mar 22, 2008 | Nov 2, 1999 | none ahead |
| Sun Pharmaceutical Industriesits history only | 50 open or running | phase 1since Oct 15, 2008 | Oct 15, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Pfizerits history only | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 31, 2008 | Mar 31, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Sep 20, 2007 | Sep 20, 2007 | none ahead |
| HK inno.Nits history only | 20 open or running | phase 1since Jan 7, 2014 | Jan 7, 2014 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 15, 2015 | Jan 15, 2015 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Antios Therapeuticsits history only | 10 open or running | phase 1since Oct 28, 2021 | Oct 28, 2021 | none ahead |
| Italfarmacoits history only | 10 open or running | phase 1since Apr 26, 2023 | Apr 26, 2023 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 1since Jul 6, 2026 | Jul 6, 2026 | none ahead |
| Phathom Pharmaceuticalsits history only | 10 open or running | phase 3since Nov 15, 2019 | Nov 15, 2019 | none ahead |
| PTC Therapeuticsits history only | 10 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| RedHill Biopharmaits history only | 10 open or running | phase 3since Dec 26, 2016 | Dec 26, 2016 | none ahead |
| Shandong Luoxin Pharmaceutical Group Stockits history only | 10 open or running | phase 1since Jun 2, 2023 | Jun 2, 2023 | none ahead |
| Sihuan Pharmaceutical Holdings Groupits history only | 10 open or running | phase 1since May 15, 2020 | May 15, 2020 | none ahead |
| Yuhanits history only | 10 open or running | phase 1since Aug 8, 2013 | Aug 8, 2013 | none ahead |
Also a collaborator on its studies: Genpharm ULC.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Nov 2, 1999.
- Aug 8, 2013Yuhan’s first study: phase 1 study in HealthyNew to YuhanYuhan · NCT01921647 · 95 enrolled · Korea, Republic of
- Jan 7, 2014HK inno.N’s first study: phase 1 study in HealthyNew to HK inno.NHK inno.N · NCT02052336 · 24 enrolled · Korea, Republic of
- Sep 25, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02251769 · 24 enrolled
- Nov 4, 2014PTC Therapeutics’ first study: phase 1 study in Healthy VolunteersNew to PTC TherapeuticsPTC Therapeutics · NCT02286635 · 58 enrolled · United States
- Jan 15, 2015Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02343289 · 18 enrolled · Belgium
- Dec 13, 2016Phase 1 study in Drug InteractionHK inno.N · NCT03011996 · 60 enrolled · Korea, Republic of
- Dec 26, 2016RedHill Biopharma’s first study: phase 3 study in Crohn DiseaseNew to RedHill BiopharmaRedHill Biopharma · NCT03009396 · 54 enrolled · United States, Canada, Czechia and more
- Jan 9, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03800550 · 16 enrolled · Belgium
- Nov 15, 2019Phathom Pharmaceuticals’ first study: phase 3 study in Helicobacter Pylori InfectionNew to Phathom PharmaceuticalsPhathom Pharmaceuticals · NCT04167670 · 1,046 enrolled · United States, Bulgaria, Czechia and more
- May 15, 2020Sihuan Pharmaceutical Holdings Group’s first study: phase 1 study in Healthy Male VolunteersNew to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT04444011 · 32 enrolled
- Oct 28, 2021Antios Therapeutics’ first study: phase 1 study in Drug Drug InteractionNew to Antios TherapeuticsAntios Therapeutics · NCT05137600 · 36 enrolled · Canada
- Apr 26, 2023Italfarmaco’s first study: phase 1 study in Drug Drug InteractionNew to ItalfarmacoItalfarmaco · NCT05845567 · 20 enrolled · Portugal
- Jun 2, 2023Shandong Luoxin Pharmaceutical Group Stock’s first study: phase 1 study in HealthyNew to Shandong Luoxin Pharmaceutical Group StockShandong Luoxin Pharmaceutical Group Stock · NCT05915871 · 22 enrolled · China
- Jul 6, 2026Jiangsu HengRui Medicine’s first study: phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07696091 · 40 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2026 | 40 |
| NCT05915871Healthy · China | 1 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Apr 28, 2023 | 22 |
| NCT05845567Drug Drug Interaction · Portugal | 1 | Completed | Italfarmaco | May 8, 2022 | 20 |
| NCT05137600Drug Drug Interaction · Canada | 1 | Completed | Antios Therapeutics | Dec 23, 2021 | 36 |
| NCT04444011Healthy Male Volunteers | 1 | UNKNOWN | Sihuan Pharmaceutical Holdings Group | Sep 30, 2020 | 32 |
| NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more | 3 | Completed | Phathom Pharmaceuticals | Mar 10, 2021 | 1,046 |
| NCT03800550Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jun 4, 2019 | 16 |
| NCT03009396Crohn Disease · United States, Canada, Czechia and more | 3 | Completed | RedHill Biopharma | Nov 13, 2018 | 54 |
| NCT03011996Drug Interaction · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2017 | 60 |
| NCT02343289Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2015 | 18 |
| NCT02286635Healthy Volunteers · United States | 1 | Completed | PTC Therapeutics | Dec 2014 | 58 |
| NCT02251769Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2003 | 24 |
| NCT02052336Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jan 2014 | 24 |
| NCT01921647Healthy · Korea, Republic of | 1 | Completed | Yuhan | Nov 2013 | 95 |
| NCT00881738Healthy | 1 | Completed | Novartis | Jun 2002 | 32 |
| NCT00881179Healthy | 1 | Completed | Novartis | Jun 2002 | 24 |
| NCT00840411Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2002 | 66 |
| NCT00840216Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Aug 2002 | 22 |
| NCT00836706Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2002 | 24 |
| NCT00835692Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2002 | 60 |
| NCT00775372Healthy · India | – | Completed | Sun Pharmaceutical Industries | Oct 2005 | 40 |
| NCT00775255Healthy · India | – | Completed | Sun Pharmaceutical Industries | Sep 2005 | 40 |
| NCT00774696Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Dec 2002 | 24 |
| NCT00774644Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Jan 2003 | 33 |
| NCT00774189Healthy · India | 1 | Completed | Sun Pharmaceutical Industries | Aug 2003 | 32 |
| NCT00648960Healthy · Canada | 1 | Completed | Viatris | Jul 2003 | 64 |
| NCT00648830Healthy · Canada | 1 | Completed | Viatris | Jun 2004 | 32 |
| NCT00648128Healthy · Canada | 1 | Completed | Viatris | Mar 2003 | 44 |
| NCT00645086Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). · United States, Canada, Puerto Rico | 3 | Completed | Abbott | Apr 2004 | 465 |
| NCT00644553Acute Bacterial Sinusitis (ABS) · United States, Canada, Greece and more | 3 | Completed | Abbott | Mar 2004 | 437 |
| NCT00643227Pneumonia · United States, Argentina, Canada and more | 3 | Completed | Pfizer | 504 | |
| NCT00602498Infections · United States | – | Completed | Hikma Pharmaceuticals | Mar 2003 | 28 |
| NCT00601315Infections · United States | – | Completed | Hikma Pharmaceuticals | May 2003 | 40 |
| NCT00002336HIV Infections · United States | – | Completed | Abbott | Nov 1994 | |
| NCT00002331HIV Infections · United States, Puerto Rico | – | Completed | Abbott | Mar 1995 | |
| NCT00002194HIV Infections · United States | 1 | Completed | Boehringer Ingelheim | 36 | |
| NCT00002140Mycobacterium avium-intracellulare Infection · United States | 3 | Completed | Pfizer | ||
| NCT00002101Mycobacterium avium-intracellulare Infection · United States | 3 | Completed | Pfizer | 450 | |
| NCT00000971Mycobacterium avium-intracellulare Infection · United States | 1 | Completed | Abbott | 24 |
How it is read
Names in the registry
- “Clarithromycin”, 23 entries
- “clarithromycin”, 2 entries
- “Clarithromycin ER 500 mg tablets”, 2 entries
- “Clarithromycin 500mg”, 2 entries
- “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry
Conditions, from the studies’ own filings
- Mycobacterium avium-intracellulare Infection, 3 studies
- Infections, 2 studies
- HIV Infections, 2 studies
- Bronchiectasis, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.